Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Novel Two-Prong Biologic Shows Promise in Asthma

(MedPage Today) -- The unique dual inflammation blockade of investigational lunsekimig showed promise for moderate-to-severe asthma in the phase II AIRCULES study. Targeting both thymic stromal lymphopoietin (TSLP) and interleukin (IL)-13, lunsekimig...

Novel Two-Prong Biologic Shows Promise in Asthma

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Thursday 10 September →